un Call IMI-2 sur la thématique vaccination & immuno-senescence (healthy aging) vient d’être lancé.
This section is dedicated to share publications previously approved by the CoReVac steering committee as major contributions to the field. In line with the CoReVac objective to stimulate the french vaccine community, papers from french teams will be prioritised. But as we also try to extend the CoReVac network to an european level, we will open the section to european papers and we are encouraging you to send us and share any oustanding papers you can think about.
- The paper of this month and first paper of the section, published on the Lancet Infectious Disease, is related to chikungunya vaccine development and first in human clinical trial. The vaccine come from the Frederic Tangy unit and is based on measle recombinant vector.
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial
- The second paper of the section is dedicated to ebola vaccine. Interim analysis of rVSV-EBOV ring vaccine trial in Guinea show great promises.
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial